Creating tomorrow’s immunotherapies

NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, that has been supported and financed by BaseLaunch. The company builds on decades of pioneering research by founders Prof. Jean Pieters and Dr. Rajesh Jayachandran – the current CSO – into the molecular mechanisms regulating T-cell function and homeostasis. This work has generated key insights into previously unexplored biology that, when targeted, enables modulation of inflammatory T cells while preserving overall immunocompetence.

NXI is headed by Dr. Ruben Herrendorff, a proven biotech entrepreneur who previously co-founded and led Polyneuron – a former BaseLaunch portfolio company – through multiple financing rounds and into the clinic. Filippo Oliveri, a successful life sciences entrepreneur and co-founder of NXI, played a pivotal role in launching the company and establishing its early operations.

BaseLaunch has supported NXI since its inception, providing the initial funding as well as working closely with the team to further derisk the approach and build a competitively differentiated scientific package. Importantly the BaseLaunch funding and support acted as a catalyst for raising a total of CHF 3.5 million in pre-seed financing.

Over the past year, NXI has attracted strong interest from the international life sciences investor community. Following positive due diligence outcomes, the company successfully secured a significant venture financing round with participation from top-tier global venture capital firms – reflecting both the strength of the underlying science and the team’s ability to execute.